Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors

Dina Polosukhina, Harold D. Love, Hernan Correa, Zengliu Su, Kimberly B. Dahlman, William Pao, Harold L. Moses, Carlos L. Arteaga, Harold N. Lovvorn, Roy Zent, Peter E. Clark

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Wilms tumor (WT) is the most common renal neoplasm of childhood and affects 1 in 10 000 children aged less than 15 years. These embryonal tumors are thought to arise from primitive nephrogenic rests that derive from the metanephric mesenchyme during kidney development and are characterized partly by increased Wnt/β-catenin signaling. We previously showed that coordinate activation of Ras and β-catenin accelerates the growth and metastatic progression of a murine WT model. Here, we show that activating KRAS mutations can be found in human WT. In addition, high levels of phosphorylated AKT are present in the majority of WT. We further show in a mouse model and in renal epithelial cells that Ras cooperates with β-catenin to drive metastatic disease progression and promotes in vitro tumor cell growth, migration, and colony formation in soft agar. Cellular transformation and metastatic disease progression of WT cells are in part dependent on PI3K/AKT activation and are inhibited via pharmacological inhibition of this pathway. Our studies suggest both KRAS mutations and AKT activation are present in WT and may represent novel therapeutic targets for this disease.

Original languageEnglish (US)
Pages (from-to)405-421
Number of pages17
JournalMolecular oncology
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2017

    Fingerprint

Keywords

  • AKT
  • KRAS
  • Wilms tumor
  • β-catenin

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Polosukhina, D., Love, H. D., Correa, H., Su, Z., Dahlman, K. B., Pao, W., Moses, H. L., Arteaga, C. L., Lovvorn, H. N., Zent, R., & Clark, P. E. (2017). Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Molecular oncology, 11(4), 405-421. https://doi.org/10.1002/1878-0261.12044